Z4349
Overview of the chemical compound Z4349
Z4349[edit | edit source]
Z4349 is a synthetic compound that belongs to the class of opioid analgesics. It is structurally related to viminol, a known opioid, and is characterized by its unique chemical structure that includes a pyrrolidone derivative. Z4349 has been studied for its potential use in pain management due to its analgesic properties.
Chemical Structure[edit | edit source]
Z4349 is a derivative of viminol, which is a racemic mixture of six stereoisomers. The chemical structure of Z4349 includes a pyrrolidone ring, which is a key feature that contributes to its pharmacological activity. The presence of this ring is thought to influence the compound's interaction with opioid receptors in the central nervous system.
Pharmacology[edit | edit source]
Z4349 acts primarily as an agonist at the mu-opioid receptor, which is responsible for its analgesic effects. The activation of these receptors leads to the inhibition of pain pathways in the central nervous system, providing relief from moderate to severe pain. Like other opioids, Z4349 may also interact with delta and kappa opioid receptors, although its affinity for these receptors is typically lower.
Synthesis[edit | edit source]
The synthesis of Z4349 involves several chemical reactions starting from basic organic compounds. The process includes the formation of the pyrrolidone ring and the subsequent addition of various functional groups to achieve the desired pharmacological properties.
Clinical Use[edit | edit source]
While Z4349 has shown promise in preclinical studies, its clinical use is limited. The compound is primarily of interest in research settings where it is used to study the effects of novel opioid analgesics. Its potential for development into a therapeutic agent is still under investigation, with considerations for its efficacy, safety, and potential for abuse.
Side Effects[edit | edit source]
As with other opioid analgesics, Z4349 may cause a range of side effects. Common side effects include nausea, vomiting, constipation, and drowsiness. More serious side effects can include respiratory depression, which is a significant risk associated with opioid use. The potential for addiction and tolerance is also a concern with prolonged use.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD